DF 5008
Alternative Names: DF-5008Latest Information Update: 24 Nov 2022
At a glance
- Originator Dragonfly Therapeutics
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunostimulants; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies
Most Recent Events
- 18 Nov 2022 Preclinical trials in Haematological malignancies in USA (Parenteral) prior to November 2022 (Dragonfly Therapeutics pipeline, November 2022)